These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 17495006

  • 1. Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.
    Pena A, Murat B, Trueba M, Ventura MA, Bertrand G, Cheng LL, Stoev S, Szeto HH, Wo N, Brossard G, Serradeil-Le Gal C, Manning M, Guillon G.
    Endocrinology; 2007 Sep; 148(9):4136-46. PubMed ID: 17495006
    [Abstract] [Full Text] [Related]

  • 2. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.
    J Med Chem; 2007 Feb 22; 50(4):835-47. PubMed ID: 17300166
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.
    J Med Chem; 2004 Apr 22; 47(9):2375-88. PubMed ID: 15084136
    [Abstract] [Full Text] [Related]

  • 5. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.
    J Pept Sci; 2006 Mar 22; 12(3):190-8. PubMed ID: 16130178
    [Abstract] [Full Text] [Related]

  • 6. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Mar 22; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity.
    Andrés M, Trueba M, Guillon G.
    Br J Pharmacol; 2002 Apr 22; 135(7):1828-36. PubMed ID: 11934825
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells.
    Perdonà E, Arban R, Griffante C.
    Eur J Pharmacol; 2012 Mar 15; 679(1-3):16-23. PubMed ID: 22285855
    [Abstract] [Full Text] [Related]

  • 10. Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile.
    Colson PH, Virsolvy A, Gaudard P, Charrabi A, Corbani M, Manière MJ, Richard S, Guillon G.
    Pharmacol Res; 2016 Nov 15; 113(Pt A):257-264. PubMed ID: 27586252
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.
    Guillon G, Derick S, Pena A, Cheng LL, Stoev S, Seyer R, Morgat JL, Barberis C, Gal CS, Wagnon J, Manning M.
    J Neuroendocrinol; 2004 Apr 15; 16(4):356-61. PubMed ID: 15089974
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
    Corbani M, Trueba M, Stoev S, Murat B, Mion J, Boulay V, Guillon G, Manning M.
    J Med Chem; 2011 Apr 28; 54(8):2864-77. PubMed ID: 21428295
    [Abstract] [Full Text] [Related]

  • 15. Molecular cloning and functional characterization of V2 [8-lysine] vasopressin and oxytocin receptors from a pig kidney cell line.
    Gorbulev V, Büchner H, Akhundova A, Fahrenholz F.
    Eur J Biochem; 1993 Jul 01; 215(1):1-7. PubMed ID: 8393786
    [Abstract] [Full Text] [Related]

  • 16. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C.
    J Pept Sci; 2005 Oct 01; 11(10):593-608. PubMed ID: 15880385
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.
    Marir R, Virsolvy A, Wisniewski K, Mion J, Haddou D, Galibert E, Meraihi Z, Desarménien MG, Guillon G.
    Br J Pharmacol; 2013 Sep 01; 170(2):278-92. PubMed ID: 23725319
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
    Stoev S, Cheng LL, Manning M, Wo NC, Szeto HH.
    J Pept Sci; 2006 Sep 01; 12(9):592-604. PubMed ID: 16625682
    [Abstract] [Full Text] [Related]

  • 20. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
    Nakamura S, Yamamura Y, Itoh S, Hirano T, Tsujimae K, Aoyama M, Kondo K, Ogawa H, Shinohara T, Kan K, Tanada Y, Teramoto S, Sumida T, Nakayama S, Sekiguchi K, Kambe T, Tsujimoto G, Mori T, Tominaga M.
    Br J Pharmacol; 2000 Apr 01; 129(8):1700-6. PubMed ID: 10780976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.